NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CORLOPAM (fenoldopam mesylate) is an injectable dopamine D1-receptor agonist approved in 1997 for short-term management of severe hypertension. It works by selective vasodilation of renal, coronary, and peripheral arteries through D1-receptor stimulation. The drug is primarily used in acute care settings to rapidly reduce blood pressure in hypertensive crises.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), the brand faces declining market opportunity requiring defensive commercial strategies and likely team consolidation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CORLOPAM offers limited career growth opportunities given its LOE-approaching status and zero linked job postings. Roles focus on defensive maintenance and hospital-based sales rather than growth-oriented development.
Brand ManagerMedical Science Liaison
Worked on CORLOPAM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.